Physician profile
James Chevalier
NPI 1093779936
$201,968.86
in general payments reported to CMS, 2019-2025
18 companies · $201K in 2025
The $201K reported for 2025 was more than what 99% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $654 · 2020: $84.75 · 2021: $39.38 · 2023: $17.29 · 2024: $222 · 2025: $201K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $68K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $67K · Travel and Lodging: $31K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $29K · Food and Beverage: $6,072 · Education: $53.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $68,362.46 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $67,091.20 |
| Travel and Lodging | $30,511.14 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $29,100.00 |
| Food and Beverage | $6,072.41 |
| Education | $53.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $114,045.39 | 2023-2025 | Filspari |
| Otsuka America Pharmaceutical, INC. | $78,533.28 | 2024-2025 | Voyxact, Jynarque |
| Vertex Pharmaceuticals Incorporated | $6,062.46 | 2025 | |
| Novartis Pharmaceuticals Corporation | $2,225.00 | 2025 | |
| Alexion Pharmaceuticals, INC. | $194.44 | 2019-2020 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $160.16 | 2024-2025 | |
| Mallinckrodt Enterprises LLC | $153.77 | 2019 | |
| Daiichi Sankyo INC. | $102.27 | 2019-2024 | Injectafer |
| Astrazeneca Pharmaceuticals Lp | $91.74 | 2019-2020 | |
| Akebia Therapeutics INC | $88.25 | 2019 | |
| Vifor Pharma, INC. | $72.55 | 2019 | |
| Genentech, INC. | $53.45 | 2025 | |
| Aurinia Pharma U.S., INC. | $39.38 | 2021 | |
| Veloxis Pharmaceuticals, INC. | $37.41 | 2025 | Envarsus |
| Scpharmaceuticals INC. | $32.57 | 2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $31.76 | 2020 | |
| Glaxosmithkline, LLC. | $23.39 | 2019 | |
| Mallinckrodt Hospital Products INC. | $21.59 | 2025 | Acthar |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Chevalier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.